BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:00 PM
 | 
Sep 25, 2012
 |  BC Extra  |  Clinical News

Vertex, Alios discontinue one NS5B nuc, report data for another

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and partner Alios BioPharma Inc. (South San Francisco, Calif.) discontinued development of ALS-2158 after a Phase I HCV trial of the nucleotide HCV NS5B polymerase inhibitor showed "insufficient antiviral activity to warrant proceeding with...

Read the full 186 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >